Please assess the completion status of the following clinical trial:

Trial Title: Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must have relapsed or refractory CD20+ lymphoid malignancies with either documented CNS involvement or peripheral nerve infiltration.~2. Patients 3 years of age and older are eligible after 3 patients (age 15 or older) have been treated and did not experience a dose limiting toxicity. Patient 3 to 15 years of age will follow the dose escalation schema independent of the adults.~3. ECOG performance status measure will be used. (ECOG Performance Status less than or equal to 3)~4. Adequate liver function (bilirubin less than or equal to 3 mg/dL within 24 hours of enrollment)~5. Adequate renal function (serum creatinine less than or equal to 3 mg/dL within 24 hours of enrollment)~6. Urine pregnancy test for women of childbearing potential (defined as not post-menopausal for 12 consecutive months or no previous surgical sterilizations). A negative urine pregnancy test is required within 48 hours of initiating study drug.~7. Signed informed consent~Exclusion Criteria:~1. Known active meningeal infection~2. History of severe infusion reaction to any monoclonal antibody

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intrathecal Rituximab (Type: EXPERIMENTAL): Phase I Starting Dose: Rituximab administered via lumbar puncture at dose of 10 - 25 mg twice weekly according to the dose escalation.~Phase II Rituximab Starting Dose: Maximum tolerated dose from Phase I.

Based on this trial design, predict the completion outcome and termination type (if applicable).